April 21 (Reuters) - Immunovant Inc IMVT.O:
IMMUNOVANT ANNOUNCES NEXT PHASE OF GROWTH WITH ROIVANT INCLUDING CHANGES TO ITS LEADERSHIP TEAM AND ADDITIONAL INDICATIONS SJÖGREN’S DISEASE $(SJD.UK)$ AND CUTANEOUS LUPUS ERYTHEMATOSUS $(CLE.AU)$ FOR IMVT-1402
IMMUNOVANT INC - ERIC VENKER APPOINTED AS CEO OF IMMUNOVANT
IMMUNOVANT INC - TIAGO GIRAO APPOINTED AS CFO OF IMMUNOVANT
IMMUNOVANT INC - IND CLEARED FOR IMVT-1402 IN SJD, STUDY TO INITIATE SUMMER 2025
IMMUNOVANT INC - CURRENT CASH BALANCE PROVIDES RUNWAY THROUGH GRAVES’ DISEASE READOUT IN 2027
Source text: ID:nGNX5fPccv
Further company coverage: IMVT.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.